ETFIQData as of Nov 19, 2026. · etfiq.com/funds/bbc

BBC Fact Sheet: Virtus Biotech Clinical Trials ETF

Share
$38.15
close, Nov 20, 2026

Over the year to Nov 19, 2026, BBC returned +19.6% in total and charged 0.65% a year.

1-year total return
+15.2%
to Nov 20, 2026
Expense ratio
0.65%
a year
Net assets
$32m
on Nov 19, 2026
Net flow, last 4 trading days
+$2.0m
daily basis to Nov 19, 2026

Growth of $10,000, 1 year

BBC $11,962 +19.6% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month−10.1%
3 months−30.0%
Year to date−1.1%
1 year+15.2%
3 years+109.5%
5 years−8.8%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
FIRST TRACKS BIOTHERAPEUTICS INC1.67%
MBX BIOSCIENCES INC1.24%
ATAIBECKLEY INC1.23%
MONOPAR THERAPEUTICS INC1.21%
DEFINIUM THERAPEUTICS INC1.18%
XENCOR INC1.10%
ZENAS BIOPHARMA INC1.06%
UNIQURE NV1.06%
APOGEE THERAPEUTICS INC1.02%
VOR BIOPHARMA INC0.99%

BBC top ten by weight, 11.8% of the fund, of its 131 equity positions, from the holdings filed for Jul 31, 2026.

Facts

Holds 131 stocks in biotech, 0% of its weight in S&P 500 companies · First traded Dec 17, 2014 · Benchmark Its own holdings, as of Jul 31, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, BBC Fact Sheet: Virtus Biotech Clinical Trials ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/bbc/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/bbc.